vs
科睿唯安（CLVT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是科睿唯安的1.3倍（$772.1M vs $585.5M），Revvity净利率更高（12.7% vs -6.9%，领先19.6%），Revvity同比增速更快（5.9% vs -1.4%），Revvity自由现金流更多（$161.8M vs $78.9M），过去两年Revvity的营收复合增速更高（9.0% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CLVT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$585.5M
营收增速更快
RVTY
高出7.2%
-1.4%
净利率更高
RVTY
高出19.6%
-6.9%
自由现金流更多
RVTY
多$82.9M
$78.9M
两年增速更快
RVTY
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $772.1M |
| 净利润 | $-40.2M | $98.4M |
| 毛利率 | 67.2% | — |
| 营业利润率 | 5.2% | 14.5% |
| 净利率 | -6.9% | 12.7% |
| 营收同比 | -1.4% | 5.9% |
| 净利润同比 | 61.3% | 3.9% |
| 每股收益（稀释后） | $-0.06 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTRVTY
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $772.1M | ||
| Q3 25 | $623.1M | $698.9M | ||
| Q2 25 | $621.4M | $720.3M | ||
| Q1 25 | $593.7M | $664.8M | ||
| Q4 24 | $663.0M | $729.4M | ||
| Q3 24 | $622.2M | $684.0M | ||
| Q2 24 | $650.3M | $691.7M |
净利润CLVTRVTY
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $98.4M | ||
| Q3 25 | $-28.3M | $46.7M | ||
| Q2 25 | $-72.0M | $53.9M | ||
| Q1 25 | $-103.9M | $42.2M | ||
| Q4 24 | $-191.8M | $94.6M | ||
| Q3 24 | $-65.6M | $94.4M | ||
| Q2 24 | $-304.3M | $55.4M |
毛利率CLVTRVTY
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | 53.6% | ||
| Q2 25 | 67.2% | 54.5% | ||
| Q1 25 | 65.1% | 56.5% | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | 56.3% | ||
| Q2 24 | 67.2% | 55.7% |
营业利润率CLVTRVTY
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 14.5% | ||
| Q3 25 | 7.1% | 11.7% | ||
| Q2 25 | 1.1% | 12.6% | ||
| Q1 25 | -3.5% | 10.9% | ||
| Q4 24 | -9.4% | 16.3% | ||
| Q3 24 | 3.5% | 14.3% | ||
| Q2 24 | -36.9% | 12.4% |
净利率CLVTRVTY
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | 12.7% | ||
| Q3 25 | -4.5% | 6.7% | ||
| Q2 25 | -11.6% | 7.5% | ||
| Q1 25 | -17.5% | 6.4% | ||
| Q4 24 | -28.9% | 13.0% | ||
| Q3 24 | -10.5% | 13.8% | ||
| Q2 24 | -46.8% | 8.0% |
每股收益（稀释后）CLVTRVTY
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $0.86 | ||
| Q3 25 | $-0.04 | $0.40 | ||
| Q2 25 | $-0.11 | $0.46 | ||
| Q1 25 | $-0.15 | $0.35 | ||
| Q4 24 | $-0.27 | $0.77 | ||
| Q3 24 | $-0.09 | $0.77 | ||
| Q2 24 | $-0.46 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $4.3B | — |
| 股东权益账面价值 | $4.8B | $7.3B |
| 总资产 | $10.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTRVTY
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $919.9M | ||
| Q3 25 | $318.7M | $931.4M | ||
| Q2 25 | $362.6M | $991.8M | ||
| Q1 25 | $354.0M | $1.1B | ||
| Q4 24 | $295.2M | $1.2B | ||
| Q3 24 | $388.5M | $1.2B | ||
| Q2 24 | $376.4M | $2.0B |
总债务CLVTRVTY
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益CLVTRVTY
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $7.3B | ||
| Q3 25 | $4.9B | $7.4B | ||
| Q2 25 | $5.0B | $7.6B | ||
| Q1 25 | $5.0B | $7.6B | ||
| Q4 24 | $5.1B | $7.7B | ||
| Q3 24 | $5.5B | $7.9B | ||
| Q2 24 | $5.6B | $7.9B |
总资产CLVTRVTY
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $12.2B | ||
| Q3 25 | $11.2B | $12.1B | ||
| Q2 25 | $11.4B | $12.4B | ||
| Q1 25 | $11.5B | $12.4B | ||
| Q4 24 | $11.5B | $12.4B | ||
| Q3 24 | $12.0B | $12.8B | ||
| Q2 24 | $12.1B | $13.4B |
负债/权益比CLVTRVTY
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 13.5% | 21.0% |
| 资本支出强度资本支出/营收 | 9.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $333.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CLVTRVTY
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $182.0M | ||
| Q3 25 | $181.1M | $138.5M | ||
| Q2 25 | $116.3M | $134.3M | ||
| Q1 25 | $171.2M | $128.2M | ||
| Q4 24 | $141.3M | $174.2M | ||
| Q3 24 | $202.9M | $147.9M | ||
| Q2 24 | $126.2M | $158.6M |
自由现金流CLVTRVTY
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | $161.8M | ||
| Q3 25 | $115.5M | $120.0M | ||
| Q2 25 | $50.3M | $115.5M | ||
| Q1 25 | $110.3M | $112.2M | ||
| Q4 24 | $59.1M | $149.8M | ||
| Q3 24 | $126.3M | $125.6M | ||
| Q2 24 | $60.3M | $136.6M |
自由现金流率CLVTRVTY
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | 21.0% | ||
| Q3 25 | 18.5% | 17.2% | ||
| Q2 25 | 8.1% | 16.0% | ||
| Q1 25 | 18.6% | 16.9% | ||
| Q4 24 | 8.9% | 20.5% | ||
| Q3 24 | 20.3% | 18.4% | ||
| Q2 24 | 9.3% | 19.7% |
资本支出强度CLVTRVTY
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | 2.6% | ||
| Q3 25 | 10.5% | 2.6% | ||
| Q2 25 | 10.6% | 2.6% | ||
| Q1 25 | 10.3% | 2.4% | ||
| Q4 24 | 12.4% | 3.4% | ||
| Q3 24 | 12.3% | 3.3% | ||
| Q2 24 | 10.1% | 3.2% |
现金转化率CLVTRVTY
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
